Abstracts | Case Reports | Photos | SimWars
2019 competition submissions are now closed.
Authors should read the abstract submission instructions carefully. The deadline and space requirements are strictly enforced in order to give all authors an equal opportunity to submit their data in the same amount of space and under the same time constraints.
- Resident or Medical Student Status
In order to be eligible for consideration, the first author and principal investigator of each abstract submitted must be either a (1) resident in an ACGME, AOA, or ACGME-I accredited emergency medicine training program or (2) medical student in an LCME/COCA accredited institution with a strong interest in emergency medicine as a future profession, or a medical student with a strong interest in emergency medicine whose country is found within the Directory of Organizations that Recognize/Accredit Medical Schools (DORA). To verify this, each submission must be signed by the appropriate designated official (e.g., program director, dean).
- Electronic submission deadline for abstracts/posters is April 1, 2019
- There is no fee for submitting an abstract/poster. All submissions must be sent in PowerPoint®/PDF electronic format
Electronic Submission Instructions
If you have questions regarding the abstract/Poster submissions for the 8th Annual FLAAEM Scientific Assembly, please call Michael Dalley, DO at (786) 245-9371 or email email@example.com.
When submitting your abstract electronically, please include the following information:
- Name of presenting author
- Title of abstract/poster
- Contact information
- Presenting Author Information
Include the presenting author’s name, address, telephone, and fax numbers, as well as an email address. Only the presenting author listed on the submission form will be notified of abstract acceptance.
Indicate what monies have funded the research.
- Disclosure of Relevant Financial Relationships
In accordance with the essentials and standards set forth by the Accreditation Council for Continuing Medical Education, as well as guidelines proposed by the Food and Drug Administration and endorsed by the American Medical Association, an author with a conflict of interest with the content of their abstract must disclose that conflict prior to presentation. A conflict of interest includes, but is not limited to, any relevant financial relationship in a company, product or procedure mentioned in the abstract or in the presentation to be given at the conference. The authors must complete the disclosure form included in the electronic submission. A conflict in and of itself will not eliminate an abstract from consideration.
- Previous Presentations of Abstracts
No abstract published as an article on or before April 1, 2019, may be submitted for this competition.
- Informed Consent
Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966; 14:103) and must meet all the requirements governing informed consent of the country in which the research was performed.
- Use 12-point Times New Roman (or similar) type. If Times New Roman is unavailable, other options include Helvetica or Courier. Limit text to 2,500 characters, including spaces, and single space all text in the body of the abstract.
- Do not indent the title. Capitalize only the first letter of each word in the title. List author names using initials only for first and middle names. Underline author names continuously. Include institution, city, and state where research was performed. Omit degrees, titles, institutional appointments, street addresses, and ZIP codes. Single space entire abstract. The left-hand margin of the abstract’s text should be perfectly aligned.
- Use of abbreviations — The use of standard abbreviations is desirable. A special or unusual abbreviation should be placed in parentheses after the first appearance of the full word it represents. Numerals rather than words should indicate numbers, except to begin sentences.
- Use of drug names — Each time a proprietary drug name is used in the abstract, the first letter is capitalized. Non-proprietary (generic) drug names are preferred and are not capitalized.
- Structuring the abstract — Structured abstracts facilitate explicit presentation of critical information and objective assessment of scientific validity. Each abstract should include the following topic headings. It is not necessary to begin a new line or leave extra space between topic headings.
Objectives: A precise statement of the purpose of the study or the pre-study hypothesis. This may be preceded by a brief introduction summarizing past work or relevant controversies that place the study in perspective.
Methods: A brief statement of the methods used, including pertinent information about the study design, setting, participants, subjects, interventions, and observations.
Results: A summary of the results presented in sufficient detail to support the conclusions.
Conclusions: Conclusions should be succinctly stated and firmly supported by the data presented. Note important limitations.
- No submission published on or before April 1, 2019 will be accepted
- Notification of Abstract Selection
Authors of all abstracts submitted by April 1, 2019, will receive notification of acceptance or rejection by April 8, 2019.
- Withdrawals and Revisions
Withdrawals and revisions must be received in writing by April 1, 2019. No changes will be possible after that date.
Case Report Abstract Format
- Title – The title is a summary of the abstract itself and should convince the reader that the topic is important, relevant, and innovative.
- Authors – Include name, degree and institutional affiliation. The authors included should be those who contribute significantly to the intellectual content of the case report.
- Introduction - Describe the context of the case and explain its relevance and importance. Describe whether the case is unique. If not, does the case have an unusual diagnosis, prognosis, therapy or harm? Is the case an unusual presentation of a common condition? Or an unusual complication of a disease or management? Describe the instructive or teaching points that add value to this case. Does it demonstrate a cost-effective approach to management or alternative diagnostic/treatment strategy? Does it increase awareness of a rare condition?
- Case description – Follow the basic rules of medical communication. Report the case in sequence. Describe the history, examination and investigations adequately. Is the cause of the patient's illness clear-cut? What are other plausible explanations? Describe the treatments adequately. Have all available therapeutic options been considered? Are outcomes related to treatments? Include the patient’s progress and outcome.
- Discussion – Discuss rationale for decisions that were made and the lesson from the case. Report a literature review of other similar cases. Describe how this case is different from those previously reported. Explain the rationale for reporting the case. What is unusual about the case? Does it challenge prevailing wisdom? In the future, could things be done differently in a similar case?
Photo submissions must be accompanied by a brief case history written as an “unknown” in the following format
- Chief complaint
- History of present illness
- Pertinent physical exam (other than what is depicted in the photo)
- Pertinent laboratory data
- One or two questions asking the viewer to identify the diagnosis or pertinent finding.
Discussion and Pearls
In a separate Word document, please list the following information
- Answer(s) and brief discussion of the case, including an explanation of the findings in the photo
- One to three bulleted take home points or “pearls.” The answers and learning points must be mounted as a separate display.
All acceptances are expected to bring a 36” x 48” poster to the FLAAEM conference to participate in person for an oral competition.
Friday, May 10, 2019
2:00pm-4:00pm Student Team Competition
4:0pm-6:00pm Resident Team Competition
SimWars is a simulation-based competition between teams of EM residents. The exercise involves various aspects of patient scenarios emphasizing team work, as well as individual decision making and assessment.
If you are interested in participating, please sign-up when registering to attend the 8th FLAAEM Scientific Assembly. You will be contacted about establishing a team(s) from your residency program to compete in the 2019 SimWars Competition.
Please contact firstname.lastname@example.org with any questions.